Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells.

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Abstract Text:

Sonali Ghosh,Putul Maity,Sonali Ghosh,Putul Maity,Sonali Ghosh,Putul Maity,

Our previous studies with EAC tumor model demonstrated that a VEGF polyclonal antibody combined with cisplatin inhibited tumor growth. Here we report the antitumor effect of VEGF antibody plus cisplatin on a murine metastatic tumor model specially emphasizing its effect on different angiogenic parameters both in vitro and in vivo. Mouse B16F10 melanoma cells were cultured in vitro in DMEM media containing 10% FBS, nonessential amino acids and antibiotics in a 5% CO(2) incubator at 37 degrees C and the effect of VEGF antibody singly and in combination with cisplatin on this cell was assessed by MTT assay, matrigel invasion study and MMP-9 expression study in vitro. In vivo studies were performed by two tumor models viz B16F10 solid tumor model and B16LuF10 lung tumor model. The mice treated with VEGF antibody (PAb) alone, cisplatin alone and combination of VEGF antibody and cisplatin on alternative days from the next day of tumor transplantation. Antitumor as well as antiangiogenic efficacy was monitored by measuring tumor burden, survivability, MVD measurement, serum NO value measurement and bcl-2 expression study. It was observed that administration of combined therapy with VEGF antibody and cisplatin augmented antitumor activity in B16F10 melanoma models than the either agents alone. Thus our experiments show a successful VEGF antibody based combination therapy with cisplatin and suggests that the enhancement of antitumor activity could be explained by a concomitant effect on both endothelial and tumor cell compartment.

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Publishing Authors By Initials

S Ghosh,P Maity,S Ghosh,P Maity,S Ghosh,P Maity,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International immunopharmacology

VOLUME: 7

Page Numbers: 1598-608

Journal Abbreviation:

ISSN: 1567-5769

DAY: 20

MONTH: 09

YEAR: 2007

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100965259

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells.

AFFILIATION: Department of Metabolic Regulation, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata-700026, India.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int Immunopharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells Related Publications

• A case of factitious disorder involving eyes.
• Acivicin with glutaminase regulates proliferation and invasion of human MCF-7 and OAW-42 cells--an in vitro study.
• Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells.
• CBF/NF-Y controls endoplasmic reticulum stress induced transcription through recruitment of both ATF6(N) and TBP.
• Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
• Effects of inorganic nutrient levels on the biodegradation of benzene, toluene, and xylene (BTX) by Pseudomonas spp. in a laboratory porous media sand aquifer model.
• HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.
• Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation.
• Microhydration of NO3(-): a theoretical study on structure, stability and IR spectra.
• Microhydration of X(2) Gas (X = Cl, Br, and I): A Theoretical Study on X(2).nH(2)O Clusters (n = 1-8).
• Modulation of metastatic potential of B16F10 melanoma cells by acivicin: synergistic action of alutaminase and potentiation of cisplatin cytotoxicity.
• Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.
• Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
• The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.